Nov 20, 2026
Back on June 12, 2⁰26 The Economist wrote:
Scientists are not usually an excitable bunch. So when many thousands of them gave a standing ovation at a conference in Chicago, it meant something special had happened. The applause was for the results of clinical trials of a drug called daraxonrasib, developed by Revolution Medicines, a company based in California. It is designed to treat pancreatic cancer. The drug almost doubled median survival times from 6.7 months to 13.2 months.
Rasonque (generic name daraxonrasib) is a once-daily oral RAS-targeted therapy approved by the U.S. Food and Drug Administration (FDA) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or cannot receive multiagent systemic therapy.
Take a look at this link from Memorial Sloan Kettering Cancer Center: https://www.mskcc.org/news/how-daraxonrasib-could-improve-pancreatic-cancer-treatment-offering-new-hope